Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin

American Journal of Pathology

Volumn 177, Issue 3, 2010, Pages 1087-1094

  Park, Joon Tae ^a   Chen, Xu ^a   Tropè, Claes G ^b   Davidson, Ben ^b,c   Shih, Ie Ming ^a   Wang, Tian Li ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; KRUPPEL LIKE FACTOR 4; MULTIDRUG RESISTANCE PROTEIN 1; NOTCH3 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NAC1; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR REX1; TRANSCRIPTION FACTOR RIF1; TRANSCRIPTION FACTOR SALL4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER RESISTANCE; CELL GROWTH; CELL SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; EMBRYONIC STEM CELL; EPITHELIUM CELL; FEMALE; GENE AMPLIFICATION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IC 50; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

EID: 77956522571     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100316     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249
2. Park JT, Li M, Nakayama N, Davidson B, Eberhart CG, Kurman RJ, Shih I-M, Wang T-L: Notch-3 gene amplification in ovarian cancer. Cancer Res 2006, 66:6312-6318
3. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004, 10:3291-3300 (Pubitemid 38685433)
4. Dubeau L: Ovarian cancer. The Metabolic and Molecular Basis of Inherited Disease, ed 8. Edited by CR Scriver, AL Beaudet, WS Sly, D Valle, B Childs, KW Kinzler, B Vogelstein: New York, McGraw-Hill, 2001, pp 1091-1096
5. Berek JS, Martinez-Maza O: Molecular and biologic factors in the pathogenesis of ovarian cancer. J Reprod Med 1994, 39:241-248 (Pubitemid 24125862)
6. Park JT, Shih Ie M, Wang TL: Identification of pbx1, a potential oncogene, as a notch3 target gene in ovarian cancer. Cancer Res 2008, 68:8852-8860
7. Cho KR, Shih IM: Ovarian cancer. Annu Rev Pathol Mech Dis 2009, 4:287-313
8. Higgins CF: Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007, 446:749-757 (Pubitemid 46582024)
9. Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, Wang TL: Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA 2005, 102:14004-14009 (Pubitemid 41377693)
10. Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL, Shih Ie M: Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res 2009, 69:1407-1415
11. Nakayama K, Nakayama N, Davidson B, Sheu JJ, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL, Shih Ie M: A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 2006, 103:18739-18744 (Pubitemid 44913480)
12. Jinawath N, Vasoontara C, Yap KL, Thiaville MM, Nakayama K, Wang TL, Shih IM: NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene 2009, 28:1941-1948
13. Song J, Shih Ie M, Chan DW, Zhang Z: Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia 2009, 11:605-614, 1 p following 614
14. Song J, Shih Ie M, Salani R, Chan DW, Zhang Z: Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 2007, 13:6842-6849 (Pubitemid 350206823)
15. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR: Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005, 96:287-295 (Pubitemid 40127123)
16. Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L: Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 2007, 105:31-44 (Pubitemid 46441466)
17. Kleinberg L, Florenes VA, Silins I, Haug K, Trope CG, Nesland JM, Davidson B: Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 2007, 109:228-238 (Pubitemid 46106237)
18. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005, 103:1631-1643
19. Davidson B, Trope CG, Wang TL, Shih Ie M: Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol 2006, 103:814-819 (Pubitemid 44821313)
20. Davidson B, Alejandro E, Florenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC: Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer 2004, 100:2139-2147 (Pubitemid 38580332)
21. Shih IM, Wang TL: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007, 67:1879-1882 (Pubitemid 46424200)
22. Wang JLD, Orkin SH: Requirement of Nanog dimerization for stem cell self-renewal and pluripotency. Proc Natl Acad Sci USA 2008, 105:6326-6331
23. Wang JRS, Chu J, Shen X, Levasseur DN, Theunissen TW, Orkin SH: A protein interaction network for pluripotency of embryonic stem cells. Nature 2006, 444:364-368 (Pubitemid 44764111)
24. Gu G, Yuan J, Wills M, Kasper S: Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007, 67:4807-4815 (Pubitemid 46910189)
25. Bourguignon LY, Peyrollier K, Xia W, Gilad E: Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008, 283:17635-17651
26. Mitsui KTY, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003, 113:631-642 (Pubitemid 36694188)
27. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih Ie M: Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005, 65:1994-2000 (Pubitemid 40478629)
28. Davidson B: Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature. Anal Cell Pathol 2001, 23:107-128
29. Dang L, Fan X, Chaudhry A, Wang M, Gaiano N, Eberhart CG: Notch3 signaling initiates choroid plexus tumor formation. Oncogene 2006, 25:487-491 (Pubitemid 43117634)
30. Buckhaults P, Zhang Z, Chen YC, Wang TL, St Croix B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, Shih Ie M: Identifying tumor origin using a gene expression-based classification map. Cancer Res 2003, 63:4144-4149 (Pubitemid 36917939)
31. Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap KL, Guo T, Lee CS, Wang W, Balgley BM, Davidson B, Wang TL, Shih IM: Oncoproteomic analysis reveals coupregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS ONE, 5:e11198, 2010. PMID: 20585448